Wegovy vs Retatrutide: Cost and Access Head-to-Head

The Efficacy Gap Between These Two Drugs Is Real

Retatrutide delivered markedly greater percentage weight loss in its phase 2 trial than Wegovy showed in STEP-1, though the trials were not head-to-head and differed in design, duration, and population. Any cross-trial comparison requires caution. The numbers, however, set a clear directional signal.

In STEP-1 (N=1,961), participants receiving semaglutide 2.4 mg once weekly achieved 14.9% mean body-weight loss at 68 weeks compared with 2.4% in the placebo group [1]. That result anchored Wegovy's FDA approval and established semaglutide as the benchmark GLP-1 agonist for obesity treatment.

Retatrutide's phase 2 dose-finding study (N=338) reported 24.2% mean body-weight loss at the 12 mg dose over 48 weeks, with weight curves still trending downward at study end [2]. The triple-agonist mechanism, engaging GLP-1, GIP, and glucagon receptors simultaneously, appears to drive energy expenditure and appetite suppression through complementary pathways. "The glucagon receptor component may increase resting energy expenditure, adding a thermogenic effect that single-agonist GLP-1 drugs do not provide," noted the Jastreboff et al. publication in the New England Journal of Medicine [2].

The 48-week retatrutide trial was shorter than STEP-1's 68-week duration. Participants had not yet reached a weight plateau, meaning final efficacy at a comparable timepoint could be higher or could plateau closer to Wegovy's range. Phase 3 data will clarify that question. Still, the 24.2% vs. 14.9% difference is large enough that most obesity medicine specialists consider retatrutide a potential step forward if phase 3 confirms the signal.

Wegovy's Current Price and the Savings Programs That Actually Help

Wegovy carries a wholesale acquisition cost (WAC) of approximately $1,349.02 per 28-day supply, a figure that places it among the most expensive chronic-use medications in primary care. The actual out-of-pocket cost varies enormously depending on insurance tier, employer carve-outs, and manufacturer discount programs.

Novo Nordisk offers a savings card that can reduce copays to as low as $0 for eligible commercially insured patients, though the benefit caps at a defined annual limit [3]. Patients without commercial coverage or whose plans exclude anti-obesity medications face the full list price. Medicare Part D has historically excluded obesity drugs, although the Treat and Reduce Obesity Act and subsequent policy shifts have begun to change that calculus. As of early 2026, Medicare coverage for Wegovy remains limited to patients with specific cardiovascular indications following the SELECT trial results.

The SELECT trial (N=17,604) demonstrated a 20% reduction in major adverse cardiovascular events (MACE) with semaglutide 2.4 mg compared with placebo over a mean follow-up of 39.8 months [4]. That cardiovascular benefit shifted the insurance conversation. Several large commercial payers expanded Wegovy coverage after SELECT, treating the drug as a cardiovascular risk reducer rather than a cosmetic weight-loss product.

Approximate out-of-pocket ranges for Wegovy in 2026:

• Commercial insurance with coverage: $0 to $300/month
• Commercial insurance without obesity drug coverage: $1,349/month
• Medicare (cardiovascular indication): variable, $50 to $500/month depending on plan
• Cash pay without savings card: $1,349/month

Retatrutide Has No Price Because It Has No Approval

Retatrutide (LY3437943), developed by Eli Lilly, remains in phase 3 clinical trials as of May 2026. No regulatory agency has approved the drug. No list price exists. No insurance formulary includes it. Any "cost" figure circulating online for retatrutide refers either to research-grade peptides sold by unregulated compounding sources or to speculative projections, neither of which reflects what a commercially approved product would cost.

Eli Lilly's pricing of tirzepatide (Mounjaro/Zepbound), another multi-agonist from the same pipeline, offers the closest proxy. Zepbound launched at a list price of $1,059.87 per month [5], roughly 21% below Wegovy's WAC. If Lilly follows a similar pricing strategy for retatrutide, a range of $1,000 to $1,400 per month would be plausible. That is projection, not fact.

The regulatory timeline matters for access planning. Eli Lilly's phase 3 program for retatrutide includes multiple trials across obesity, type 2 diabetes, and metabolic dysfunction-associated steatotic liver disease (MASLD). Typical FDA review timelines suggest the earliest possible approval could fall in late 2026 or 2027, though delays are common in large metabolic programs. Patients considering retatrutide should plan around a timeline measured in quarters, not weeks.

Insurance Coverage: One Drug You Can Fight For, One You Cannot

Wegovy insurance battles are well-documented. About half of commercial health plans now include some form of GLP-1 agonist coverage for obesity, according to survey data from the Obesity Action Coalition [6]. Coverage does not mean easy access. Prior authorization requirements typically demand documented BMI of 30 or above (or 27 with a comorbidity), evidence of failed lifestyle intervention, and sometimes a trial of older medications like phentermine or orlistat.

Denial rates remain high. A 2023 analysis found that approximately 40% of initial prior authorization requests for anti-obesity medications were denied, with success rates improving substantially on appeal [6]. Patients who document their clinical history thoroughly and whose prescribers submit peer-to-peer reviews when needed succeed more often.

Retatrutide cannot be submitted to any insurance formulary until it receives regulatory approval. Even after approval, formulary inclusion typically lags 6 to 18 months as pharmacy benefit managers negotiate rebates and assign tier placement. Early adopters of newly approved GLP-1 drugs often face a coverage gap during this period. The experience with Zepbound's launch is instructive: despite competitive pricing, many plans took 6 to 12 months to add it to preferred formularies.

"Formulary decisions for novel anti-obesity agents are driven more by rebate negotiations than by clinical differentiation," according to a 2024 report from the Institute for Clinical and Economic Review (ICER) [7]. That dynamic means retatrutide's superior efficacy data may not translate into faster or broader coverage if Eli Lilly's rebate structure is less favorable than Novo Nordisk's.

Supply Chain Realities Favor Wegovy Right Now

Wegovy experienced severe supply shortages throughout 2022 and 2023, with Novo Nordisk restricting starter doses and pausing new patient starts at various points. By mid-2025, the company had expanded manufacturing capacity sufficiently to restore full-dose availability across U.S. pharmacies. The shortage period, while frustrating, is largely resolved.

Retatrutide faces the opposite problem. It does not exist as a commercial product. No manufacturing infrastructure for scaled commercial production has been publicly disclosed by Eli Lilly, though the company has invested over $9 billion in U.S. manufacturing expansion across its injectable portfolio. If retatrutide follows the trajectory of tirzepatide, supply constraints in the first 12 to 18 months post-launch are likely.

Compounding pharmacies have filled part of the GLP-1 supply gap by producing semaglutide and tirzepatide copies under FDA shortage provisions. The FDA's updated guidance on compounded GLP-1 receptor agonists clarified that once a shortage is resolved, compounders must cease production of copies of the branded drug [8]. Retatrutide compounding would face similar regulatory constraints, and sourcing research-grade retatrutide peptides from unregulated suppliers carries significant safety risks including unknown purity, incorrect dosing, and contamination.

Head-to-Head Trial Data Does Not Exist Yet

No randomized controlled trial has directly compared Wegovy and retatrutide in the same patient population. The 14.9% vs. 24.2% comparison is a cross-trial estimate with all the limitations that implies. Differences in baseline BMI, patient demographics, trial duration, titration schedules, and endpoint definitions make precise comparison unreliable.

The STEP-1 population had a mean baseline BMI of 37.9 and a mean body weight of 105.3 kg [1]. The Jastreboff phase 2 retatrutide population had a mean baseline BMI of 37.3 and mean body weight of 107.5 kg at the 12 mg dose level [2]. These baselines are reasonably similar, which strengthens the cross-trial comparison somewhat, but confounders remain.

What can be stated with reasonable confidence: retatrutide's triple-agonist mechanism produced numerically greater weight loss in a shorter trial duration. Whether that magnitude holds in larger, longer phase 3 studies is the central unanswered question. The ongoing TRIUMPH phase 3 program will provide that answer.

For patients making decisions today, the comparison is not really Wegovy vs. retatrutide. It is Wegovy now vs. waiting for retatrutide later. That framing changes the calculus significantly.

Switching From Wegovy to Retatrutide: What We Know

No published protocol governs switching from semaglutide to retatrutide. Clinical trial participants in retatrutide studies were required to wash out prior GLP-1 agonist therapy before enrollment, which tells us nothing about real-world transition protocols.

Based on pharmacological principles, a transition would likely involve completing the current Wegovy dose cycle, allowing a washout period of 5 to 7 half-lives (semaglutide's half-life is approximately 7 days, so 5 to 7 weeks), and then initiating retatrutide at the lowest titration dose. This approach minimizes overlapping GLP-1 receptor stimulation and allows cleaner assessment of retatrutide tolerability.

Some clinicians may eventually opt for a direct switch with abbreviated washout, particularly if gastrointestinal tolerability on Wegovy was well-established. Until peer-reviewed transition data or society guidelines exist, the conservative approach is the standard recommendation. Patients currently stable on Wegovy should not discontinue therapy in anticipation of retatrutide availability.

Side Effect Profiles Share a GLP-1 Core but Diverge on Glucagon Effects

Both drugs produce the expected GLP-1 class side effects. Nausea is the most common. In STEP-1, nausea occurred in 44.2% of semaglutide patients vs. 17.4% on placebo [1]. In the retatrutide phase 2 trial, nausea rates at the 12 mg dose reached 45.4% [2]. The similarity is expected given shared GLP-1 receptor activation.

The glucagon receptor agonism in retatrutide introduces a distinct pharmacological effect not present with Wegovy. Glucagon raises hepatic glucose output and stimulates lipolysis. In the phase 2 trial, mild transient increases in heart rate (2 to 4 bpm above placebo) were observed with retatrutide, potentially attributable to the glucagon component [2]. No clinically significant cardiac events were reported, but phase 3 safety monitoring will examine cardiovascular outcomes more rigorously.

Retatrutide also produced dose-dependent increases in energy expenditure in preclinical models. Whether this translates to meaningful metabolic advantages or additional side effects in long-term human use remains to be determined. The Endocrine Society's 2024 clinical practice guideline on obesity pharmacotherapy notes that multi-receptor agonists may require more nuanced safety monitoring than single-target agents [9].

Who Should Consider Each Drug Right Now

Wegovy is the appropriate choice for patients who meet FDA-approved indications (BMI ≥30, or ≥27 with at least one weight-related comorbidity), have insurance coverage or can manage the out-of-pocket cost, and want to start treatment without delay. Patients with established atherosclerotic cardiovascular disease gain an additional benefit supported by the SELECT trial's MACE reduction data [4].

Retatrutide is appropriate only for patients enrolled in clinical trials. No other legal, quality-assured access pathway exists in the United States as of May 2026. Patients interested in retatrutide should discuss trial eligibility with their prescriber or search ClinicalTrials.gov for active TRIUMPH program sites [2].

A 68-year-old patient with BMI 38, type 2 diabetes, and coronary artery disease should not wait for retatrutide. A 42-year-old patient with BMI 32 and no comorbidities who is ambivalent about starting Wegovy might reasonably choose to monitor the retatrutide regulatory timeline while pursuing behavioral interventions. Clinical context dictates the decision, not a blanket recommendation.

The Endocrine Society guideline recommends initiating pharmacotherapy when lifestyle interventions alone do not achieve clinically meaningful weight loss (typically defined as ≥5% of body weight) within 3 to 6 months [9].